Drug Profile
PC 112
Alternative Names: PC-112Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator PinCell
- Class Antineoplastics
- Mechanism of Action Cell surface receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Malignant melanoma
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Malignant-melanoma in Italy
- 15 Aug 2016 PC 112 is available for licensing as of 15 Aug 2016. https://sites.google.com/site/pincellsite/
- 15 Aug 2016 Early research in Malignant melanoma in Italy (unspecified route)